Skip to content
value.today

Lexaria Bioscience Corp.

LEXX
$15 Mmarket cap on Aug 1, 2026+7.1% since Jan 2024
Compare
World rank
#25,048
Revenue
$1 M
For year ending August-2025
Net income
$-12 M
-1676.1% margin
SEC filing
Employees
—

Lexaria Bioscience Corp. in brief

Lexaria Bioscience Corp. is a listed company in the Biotechnology industry, based in Canada. Its market value was $15 M on 1 August 2026, which makes it the 25,048th largest listed company in the world and the 1,255th largest in Canada on this site. In the year to August 2025 it had sales of $1 M and a net loss of $12 M. Richard Christopher is its chief executive. Its largest product and service lines by sales in 2025 were IP Licensing (99%) and B2B (1%). Its shares trade under the symbol LEXX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients using our patented DehydraTECHTM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.

DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs and glucose-dependent insulinotropic polypeptide drugs, vitamins, pain medications, hormones, antivirals, nicotine and its analogs, and cannabinoids. Our technology can be applied to a variety of therapeutic indications, including diabetes, weight loss, epilepsy, hypertension and heart disease. DehydraTECH can be implemented in a multitude of ingestible product formats including oral suspensions, tablets, capsules, foods, beverages, and oral pouches. It is suitable for use with a variety of product formats including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods.

From the company's annual report filed with the US SEC: read the report

Lexaria Bioscience Corp. timeline

3 events, 2006–2021
  1. 2006
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2016
  4. ✎
    Renamed Lexaria Bioscience Corp.
    Formerly Lexaria Corp..
  5. 2021
  6. 💰
    Record revenue of $1 million
    FY2021, the highest of the 8 years on record.

Events of Lexaria Bioscience Corp. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$7 M$14 M$21 M$28 M2023202420252026

World rank over time

▲ up 6,860 places since 2022
2022-01-07: #29227#29,22720222022-12-25: #30374#30,37420222023-07-30: #32348#32,34820232024-01-05: #30041#30,04120242026-03-08: #12037#12,03720262026-08-01: #22367#22,3672026

Rank in Canada: #1,220 (Jan 2022) · #1,198 (Dec 2022) · #1,368 (Jul 2023) · #1,133 (Jan 2024) · #51 (Mar 2026) · #802 (Aug 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
21.1×
Price / book
5.0×
Free cash flow yield
-69.8%
Net margin
-1676.1%
Operating margin
-1673.2%
Return on equity
-398.0%
Liabilities / assets
37.6%
Revenue growth
+54.3%
R&D / revenue
1160.6%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Aug 2018: revenue $0M, net income $-7M$0MFY18Fiscal year ending Aug 2019: revenue $0M, net income $-4M$0MFY19Fiscal year ending Aug 2020: revenue $0M, net income $-4M$0MFY20Fiscal year ending Aug 2021: revenue $1M, net income $-4M$1MFY21Fiscal year ending Aug 2022: revenue $0M, net income $-7M$0MFY22Fiscal year ending Aug 2023: revenue $0M, net income $-7M$0MFY23Fiscal year ending Aug 2024: revenue $0M, net income $-6M$0MFY24Fiscal year ending Aug 2025: revenue $1M, net income $-12M$1MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Aug 2025$1M+54.3%$-12M$-12M-1676.1%
Aug 2024$0M+100.0%$-6M$-6M-1260.9%
Aug 2023$0M-11.5%$-7M$-7M-2895.7%
Aug 2022$0M-63.9%$-7M$-7M-2796.2%
Aug 2021$1M+132.3%$-6M$-4M-559.7%
Aug 2020$0M+40.9%—$-4M-1316.1%
Aug 2019$0M-48.8%—$-4M-1890.9%
Aug 2018$0M——$-7M-1537.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Aug 2025$-10M$0M$-10M$-0.66—
Aug 2024$-5M$0M$-5M$-0.47—
Aug 2023$-6M$0M$-6M$-1.01—
Aug 2022$-5M$0M$-5M——
Aug 2021$-4M——$-0.95—
Aug 2020$-3M$0M$-3M$-1.47—
Aug 2019$-3M$1M$-4M$-0.05—
Aug 2018$-3M——$-0.09—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Aug 2024 (from the annual report): revenue $0M, net income $-2M$0MAug ’24Three months to Nov 2024: revenue $0M, net income $-3M$0MNov ’24Three months to Feb 2025: revenue $0M, net income $-3M$0MFeb ’25Three months to May 2025: revenue $0M, net income $-4M$0MMay ’25Three months to Aug 2025 (from the annual report): revenue $0M, net income $-3M$0MAug ’25Three months to Nov 2025: revenue —, net income $-2M—Nov ’25Three months to Feb 2026: revenue $0M, net income $-1M$0MFeb ’26Three months to May 2026: revenue —, net income $-2M—May ’26

Latest quarter to May 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to May 2026.

SEC filings

Official filings of Lexaria Bioscience Corp. with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-12 M
Net income
$-12 M

For year ending August-2025 · source: SEC filing

Balance sheet

Total assets
$4 M
Total liabilities
$2 M
Total equity
$3 M

As of August-2025

Top 15 institutional investors in Lexaria Bioscience Corp.#

As of Sep 30, 2026
15 institutions held 256,258 shares (about 1.0% of the shares outstanding) on Sep 30, 2026. The ten largest hold 1.0%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 15 largest institutional investors in Lexaria Bioscience Corp.
#InstitutionShares heldChange (shares)% heldValueFiled
1Armistice Capital, LLC172,084New0.69%$1 MNov 16, 2026
2Invenomic Capital Management LP21,578New0.09%$0 MNov 16, 2026
3Vanguard Capital Management LLC19,896New0.08%$0 MNov 13, 2026
4Geode Capital Management, LLC16,689New0.07%$0 MNov 6, 2026
5UBS Group AG12,821New0.05%$0 MNov 10, 2026
6Vanguard Fiduciary Trust Co6,278New0.03%$0 MNov 13, 2026
7Toronto Dominion Bank2,000New0.01%$0 MNov 16, 2026
8BlackRock, Inc.1,829New0.01%$0 MNov 13, 2026
9Tower Research Capital LLC (TRC)1,778New0.01%$0 MNov 16, 2026
10Vanguard Global Advisers, LLC681New0.00%$0 MNov 13, 2026
11Royal Bank Of Canada478New0.00%$0 MNov 16, 2026
12Osaic Holdings, Inc.119New0.00%$0 MNov 12, 2026
13Federation des caisses Desjardins du Quebec24New0.00%$0 MNov 16, 2026
14FMR LLC2New0.00%$0 MNov 10, 2026
15Danske Bank A/s1New0.00%$0 MNov 9, 2026

Mutual funds holding Lexaria Bioscience Corp.#

6 funds hold shares worth $0 M (about 1.7% of the company). Since their previous reports 3 added shares and 1 sold, buying $0 M net.
Mutual funds holding Lexaria Bioscience Corp.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.298,436$0 M0.78%<0.01%+34%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC171,896$0 M0.45%<0.01%+40%May 31, 2026
🇺🇸 Invenomic FundInvenomic Capital Management LP99,986$0 M0.26%<0.01%−45%Jul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC31,892$0 M0.08%<0.01%+17%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC26,138$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC11,622$0 M0.03%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Lexaria Bioscience Corp.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
13
since
$118 K-$10 K$0Jul 2024: bought $0 (0 trades), sold $10 K (1 trades)Jul 24Aug 2024: bought $5 K (1 trades), sold $0 (0 trades)AugDec 2024: bought $118 K (2 trades), sold $0 (0 trades)DecJul 2025: bought $49 K (6 trades), sold $0 (0 trades)Jul
Bought (open market)Sold (open market)Hover a month for the totals
Lexaria Bioscience Corp.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Christopher BunkaDirectorGift-100,000——273,543Form 4
filed Christopher BunkaDirectorBuyindirect+11,900$0.910$11 K281,912Form 4
filed Christopher BunkaDirectorBuyindirect+15,600$0.920$14 K270,012Form 4
filed John Martin DochertyPresident & CSO, DirectorBuy+5,376$0.930$5 K5,376Form 4
filed William Edward McKechnieDirectorBuy+5,000$0.910$5 K18,191Form 4
filed Richard ChristopherChief Executive Officer, DirectorBuy+15,000$0.910$14 K65,000Form 4
filed Vanessa CarleSecretaryBuy+750$0.910$683750Form 4
filed Christopher BunkaDirectorGrant or award+100,000——373,543Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Lexaria Bioscience Corp.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
217,377
1.1% of shares · 5.4 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1.1-for-1 split

Trading halts

  • 2026-10-09 18:07 UTC, code LUDP, resumed 18:12 UTC
  • 2026-08-03 13:59 UTC, code LUDP, resumed 14:04 UTC
  • 2026-07-31 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 1,615 shares at $3.77
  • : 153 shares at $3.30
  • : 568 shares at $3.22
  • : 2,647 shares at $3.08
  • : 1,311 shares at $2.65

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Lexaria Bioscience Corp. scorecard#

Passes 1 of the 10 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 3). Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth0 of 3
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.66 vs -0.47Diluted EPS -0.66 in fiscal 2025 against -0.47 the year before (report's currency).
    • ✗Net income higher than five years earlier-$12 M-$12 M in fiscal 2025 against -$4 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$12 MNet income -$12 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-215.8%-215.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.3×Current ratio 2.33 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-24.16Z-score -24.16 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year45.3%Diluted shares up 45.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Lexaria Bioscience Corp.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Lexaria Bioscience Corp.: statements by fiscal year
PeriodTrendFY 2025to Aug 31, 2025FY 2024to Aug 31, 2024FY 2023to Aug 31, 2023FY 2022to Aug 31, 2022FY 2021to Aug 31, 2021FY 2020to Aug 31, 2020FY 2019to Aug 31, 2019FY 2018to Aug 31, 2018FY 2017to Aug 31, 2017FY 2016to Aug 31, 2016
Income statement
Revenue706464226255723315r2234336441
Cost of revenue2.74.832721759923253046
Gross profit703459195184547215r20040834−4.9
Research and development8,2392,3613,6671,8431,263387556493549.0
General and administrative4,3453,8523,0624,960r4,9713,977r297218130r134r
Operating expenses12,5846,2136,7296,803r6,2344,364r4,3587,0171,9631,272
Operating income−11,881−5,753−6,534−6,619r−5,687————−1,277
Interest expense and finance costs————————6.02.3
Net interest income—1443———————
Non-interest income——430——————
Other non-operating income (expense)−31−56−179−765——————
Income before tax−11,911−5,809−6,713−7,384−4,170−3,987−4,158−6,609r−1,933−1,267
Income tax———06.12.318r000
Income from continuing operations———−7,384−4,164r−4,149r−4,158−6,609−1,929−1,277
Income from discontinued operations———0−2264———0
Net income including minority interests−11,911−5,809−6,713−7,384r4,186—————
Minority interests' share of net income−9.6−13−48−114−159−151−59−10−60−62
Net income attributable to shareholders−11,902−5,795−6,665−7,269−4,027r−4,085−4,158−6,609−1,929−1,277
Earnings per share, basic————-0.95-1.47r-0.05-0.09-0.03-0.03
Earnings per share, diluted-0.66-0.47-1.01—-0.95-1.47r-0.05-0.09-0.03-0.03
Shares, weighted average (diluted)18126.6—4.42.8r78715944
Balance sheet
Cash and cash equivalents1,8026,5001,3525,81310,9181,2941,2851,7272,53393
Short-term investments143r561263478341964100—
Receivables368154127r202342314r27326645131
Inventory——038301171278767135
Other current assets1,1331,188547————194150151
Current assets3,4687,8982,151r6,97812,4431,926r1,8192,2842,795510
Property, plant and equipment228255254316368483r5911.21.92.5
Right-of-use (leased) assets107r167167—911270———
Other intangible assets308517463——2922651476354
Non-current assets707970933r8568249028561486556
Total assets4,1758,8683,0847,83413,2672,828r2,6752,4322,860567
Accounts payable1,4631,066240151105r8713636r3390
Current liabilities1,4931,099268194153226r1854492434
Lease liabilities (non-current)79109——5089————
Non-current liabilities———7.450120————
Total liabilities1,5721,209404201203346r1854492479
Retained earnings−63,461−51,559−45,763−39,099−31,829−27,802−23,868−19,769−13,170−11,301
Shareholders' equity2,9908,0363,0447,94913,064r2,482r2,491r2,3882,768r266
Minority interests−387−377−364−316−202−43108—−238−178
Total equity2,6037,6592,6807,63213,0642,482r2,491r2,3882,76888
Total liabilities and equity4,1758,8683,0847,83413,2672,828r2,6752,4322,860567
Shares outstanding2020r8.16.05.7r3.0r79766851r
Cash-flow statement
Depreciation and amortization5142r145103112—————
Share-based compensation8594921707534101,1396272,602113122
Cash from operating activities−10,450−4,959−5,881−4,879−3,990−2,619r−3,006−2,518−1,546−661
Capital expenditure−25−43−34−49—0−646—0−3.1
Intangible assets bought−75−146−136−131−79−34−123−85−9.7−17
Cash from investing activities−243−189−170−181194−27−769−155−9.7−20
Debt issued—————31————
Debt repaid———0−23—————
Shares issued6,0464,209————————
Cash from financing activities6,04610,3151,590−4513,4202,654r3,3331,8673,996514
Exchange-rate effect on cash−51−20————————
Change in cash−4,6985,148−4,461—9,6248.6−442−8062,440−167
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of May 31, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Lexaria Bioscience Corp. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • IP Licensing$1 M99%
  • B2B$0 M1.4%

Business segments

  • [IP Licensing [Member]]$1 M99%

Source: SEC annual report (XBRL data) · as of Aug 31, 2025

Executive pay at Lexaria Bioscience Corp.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$893 K
Richard Christopher
Other top executives, average
$386 K
the CEO earned 2.3× this
$100 invested is now
—
Lexaria Bioscience Corp.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Richard Christopher$893 K$497 K$386 K—
2024Richard Christopher$1.4 M$1.7 M$296 K—
2023Richard Christopher$288 K$157 K$237 K—

Source: SEC proxy statement (Form DEF 14A) · as of Aug 31, 2025

Events at Lexaria Bioscience Corp.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Directors and officers 4 · Material agreement 11 · Agreement ended 1 · Unregistered share sale 6 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3

Lexaria Bioscience Corp.: events reported to the SEC
FiledWhat happenedFiling
Material agreementUnregistered share sale8-K
Delisting notice8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Delisting notice8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Agreement ended8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Shareholder vote8-K
Directors and officers8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Directors and officers8-K
Material agreement8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Shareholder vote8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Sep 9, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Lexaria Bioscience Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2025$4 MPrivate placement after listing$2 to $10 million5optionsSEC
Sep 2025$4 MPrivate placement after listing$2 to $10 million5optionsSEC
Oct 2024$5 MPrivate placement after listing$2 to $10 million1optionsSEC
Feb 2024$4 MPrivate placement after listing$2 to $10 million2optionsSEC
Oct 2023$2 MPrivate placement after listingUnder $2 million1optionsSEC
Dec 2021$1 MPrivate placement after listingUnder $2 million1equitySEC
May 2020$2 MPrivate placement after listing$2 to $10 million21equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Lexaria Bioscience Corp. compares in Biotechnology

  • Market cap$15 M · higher than 14% of 726
  • Revenue$1 M · higher than 22% of 647
  • Revenue growth54.4% · higher than 73% of 438
  • Price / sales21.1× · lower than 31% of 339
  • Price / book5.0× · lower than 31% of 534
  • FCF yield-69.8% · higher than 17% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Lexaria Bioscience Corp.🇨🇦$15 M——+54.4%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending August-2025
Balance sheet:
As of August-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Lexaria Bioscience Corp.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Lexaria Bioscience Corp.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Lexaria Bioscience Corp.? Suggest a correction